New hope for advanced stomach cancer: triple therapy shows promise
NCT ID NCT07490990
First seen Apr 02, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This study is for people with a specific type of advanced stomach cancer (HER2-positive) that has stopped responding to standard treatments. It tests a new drug (disitamab vedotin) combined with immunotherapy and targeted radiation to see if it can control the cancer longer. About 30 participants will be followed to measure how long they live without the cancer growing and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.